|
Jun 27
|
The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call
|
|
Jun 27
|
Viatris gains China approval for Yupelri to treat COPD
|
|
Jun 27
|
Viatris’ presbyopia drug clears second Phase III trial
|
|
Jun 26
|
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
|
|
Jun 26
|
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
|
|
Jun 17
|
3 Unprofitable Stocks with Mounting Challenges
|
|
Jun 17
|
3 Reasons to Avoid VTRS and 1 Stock to Buy Instead
|
|
Jun 13
|
3 Healthcare Stocks with Questionable Fundamentals
|
|
Jun 12
|
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
May 23
|
3 Stocks Under $10 Skating on Thin Ice
|
|
May 23
|
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
|
|
May 22
|
Viatris to Participate in Upcoming Investor Conferences
|
|
Apr 14
|
Is Viatris Inc. (VTRS) The Top Healthcare Stock to Buy According to Billionaire David Einhorn?
|
|
Apr 14
|
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
|
|
Apr 11
|
Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10
|
|
Apr 10
|
3 Hated Stocks with Mounting Challenges
|
|
Mar 13
|
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
|
|
Mar 11
|
1 Healthcare Stock to Target This Week and 2 to Turn Down
|
|
Feb 24
|
What's in Store for These 5 Biotech Stocks This Earnings Season?
|
|
Feb 24
|
Stay Ahead of the Game With Viatris (VTRS) Q4 Earnings: Wall Street's Insights on Key Metrics
|